This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
This was a retrospective, comparative study with a historical control that was carried out at a single centre. It was not stated whether the patients were followed-up after hospital discharge. No patient was lost to the follow-up assessment. Fellowship-trained, full-time vascular interventional radiologists performed all thrombolytic procedures.
Analysis of effectiveness
All of the patients included in the initial study sample were accounted for in the analysis of effectiveness. The outcomes used were: the hourly infused dose, the total drug dose, the infusion time, the proportions of patients with complete, or complete or partial resolution of thrombus, and the proportions of patients with major, or major or minor complications.
Complete success was defined as cases in which there was less than 5% residual thrombus. Partial success was defined as cases in which short venous segments remained that demonstrated residual narrowing or occlusion.
Major complications were defined as death, intracranial haemorrhage, pulmonary embolism, bleeding requiring transfusion or surgery, unplanned hospitalisation, or prolonged hospitalisation. Minor complications were defined as adverse events requiring minimal therapy that did not prolong hospital stay.
At baseline, the study groups were comparable in terms of their gender, age, thrombus location, duration of symptoms, and use of additional interventional therapies.
Effectiveness results
No statistically significant differences were observed in any of the outcome measures.
The rate of complete resolution of thrombus was 71.1% with UK, 65.6% with TPA, and 50% with RPA. The rates of complete or partial resolution of thrombus were 97.4% (UK), 96.9% (TPA) and 100% (RPA), respectively.
The rate of major resolution of thrombus was 5.3% with UK, 3.1% with TPA, and 8.3% with RPA. The rates of major or minor resolution of thrombus were 10.5% (UK), 12.5% (TPA) and 16.7% (RPA), respectively.
Clinical conclusions
The effectiveness analysis showed that the three treatments were comparable in their efficacy, safety and infusion times.
Measure of benefits used in the economic analysis
No summary benefit measure was used since there was no statistically significant difference between the groups in terms of the outcome measures. In effect, a cost-minimisation analysis was carried out.
Direct costs
Discounting was not relevant because of the short timeframe of the analysis. The unit costs were presented separately from the quantities of resources used. The economic evaluation considered only the cost of the three thrombolytic agents. The cost/resource boundary of the authors' institution was adopted. Resource use was estimated on the basis of retrospectively collected data that came from the same sample of patients as that used in the effectiveness study. The costs came from contractual prices at the authors' institution in July 2003.
